MARKET NEWS

Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study
Innovate Biopharmaceuticals Announces Start of First Phase 3 Clinical Trial
Deciphera Pharmaceuticals and Zai Lab Limited Announce Exclusive License Agreement
InflaRx Treats First Patient in Phase 2a Clinical Trial
Oncologie Closes $80-Million Financing for Clinical-Stage Pipeline
CytoDyn & FDA Will Meet to Potentially Finalize Protocol for Pivotal Monotherapy Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

We are your trusted global partner for the development and supply of commercial quantities of functionalized PEGs (polyethylene glycols). Those in turn, are essential for your PEGylated therapeutic proteins for drug delivery. Our offerings include high-purity materials for use in investigational products in every phase of clinical development and in commercialized products. We understand that you care about rapid and cost-effective time to market. Therefore, setting the right quality attributes for the functionalized PEG is crucial for the manufacturing and stability of your PEGylated product — we can help you get it right. And during the marketing phase, expertise in life-cycle management and regulatory affairs can help you safeguard your compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Ligand Subsidiary Vernalis & PhoreMost Limited Announce Collaboration for Novel Oncology Target

Ligand Subsidiary Vernalis & PhoreMost Limited Announce Collaboration for Novel Oncology Target

Ligand Pharmaceuticals Incorporated and PhoreMost Limited recently announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment of Maximum Plasma Levels

DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment of Maximum Plasma Levels

Druggability Technologies Holdings (DRGT) recently announced results from a pharmacokinetic study of their novel formulation of celecoxib (DRGT-46), which achieves  faster time to maximum plasma concentration (Tmax) compared to traditional celecoxib capsules.

Insilico Launches Comprehensive Portfolio of Predictive Digital Twins for Cell Culture Process Development

Insilico Launches Comprehensive Portfolio of Predictive Digital Twins for Cell Culture Process Development

In close alignment with customer needs Insilico Biotechnology AG has developed a modular suite of Digital Twins that cover key steps during bioprocess development.

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately 0 Million

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

Biogen recently announced it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.

Designing a CMC Strategy for Accelerated Development of Biotherapeutics

Designing a CMC Strategy for Accelerated Development of Biotherapeutics

As the pipeline of biologic drugs intended to treat complex disease expands, the typical timeline for drug development seems to be shortening more frequently and with more intensity……..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 26 – Controlled Release
July 10 – Prefilled Syringes